Will GLP-1s keep me from getting cancer
Any unexpected responses, particularly those inconsistent with published clinical data, may indicate product quality issues rather than true pharmacological effects
That puts retatrutide essentially on a par with bariatric surgery, says Daniel Drucker, a university professor of medicine at the University of Toronto, who has previously consulted for Eli Lilly but was not involved in the trial
(2016) examined pharmacokinetic profiles across dose ranges
, Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial, Lancet Diabetes Endocrinol